November 9, 2026 · The New England journal of medicine · DOI: 10.1056/NEJMoa2610676

Retatrutide Once Weekly in Adults with Knee Osteoarthritis Pain and Obesity.

Listen to this summary

This study tested whether retatrutide, an investigational once-weekly GIP/GLP-1/glucagon receptor triple agonist, could relieve pain from knee osteoarthritis in adults with obesity across two phase 3 trials (TRIUMPH-4 and TRIUMPH-1-OA). Retatrutide produced significantly greater reductions in WOMAC pain scores and body weight than placebo at 68 and 80 weeks, with weight loss of roughly 20–24% in TRIUMPH-4. Serious adverse events were more common with retatrutide than placebo, and gastrointestinal events were the most frequent side effects.

Thomas J Schnitzer, David J Hunter, Philip G Conaghan, Arya M Sharma, Sue D Pedersen, Kaiyi Chen, So Young Park, Nune Makarova, Kathryn Giblin, Tammy Forrester

This is one of 33,000+ journals available on OSLR. Try it free for 14 days.

Free 14-day trial. 33,000+ journals. Cancel anytime.

14-day free trial. No commitment.

“

"Oslr has become part of my weekly routine on my day off. The clinical relevance of the summaries is outstanding — I'd rate it 9/10. Being able to consume research hands-free is a huge advantage for busy physicians."

Dr. Jennifer Thompson

Dr. Jennifer Thompson

Portland, OR

Stay current without falling behind

33,000+ journals. 3-minute audio summaries. Free for 14 days.

Download on the App StoreGet it on Google Play